1. Johnson & Johnson (NYSE:JNJ)
Market Cap $615.63 billion | Beta 0.21 | Net Profit Margin 16.20%
Medicines and Medical Technology Provide Two Revenue Engines
Johnson & Johnson (NYSE: JNJ) takes the top position with the lowest supplied beta in the group and a business spanning Innovative Medicine and MedTech.
Third-quarter 2026 sales increased 5.9% to approximately $25.4 billion. Innovative Medicine revenue rose 7.7% to $16.76 billion, while MedTech sales increased 2.5% to $8.64 billion. That split illustrates the value of examining both divisions: they contribute substantial revenue, but their growth rates differ.
Management raised full-year reported sales guidance to a midpoint of $101.2 billion and adjusted earnings guidance to a midpoint of $11.10 per share. Those increases support the operating outlook, although quarterly earnings also revealed significant pressure.
Reported EPS fell to $0.09, reflecting a special charge related to the proposed talc litigation resolution and acquisition-related activity. Adjusted EPS declined 7.5% to $2.59. Revenue growth therefore did not translate into higher quarterly earnings.
That distinction is especially important when interpreting the supplied 16.20% net profit margin. The screening figure should not be confused with the margin earned in the latest quarter. Investors researching large-cap healthcare stocks still need to examine litigation costs, earnings adjustments, and the performance of each operating division.
The investment thesis rests on the breadth of the revenue base and continued product innovation. Its leading rank, however, comes from the screen’s beta measure rather than an assumption that business risks have disappeared.
Ranking Rationale
Johnson & Johnson (NYSE: JNJ) ranks first because its supplied beta of 0.21 is the lowest among the five selections. Its $615.63 billion market capitalization and 16.20% net profit margin satisfy the remaining screening requirements. Low beta indicates historically lower sensitivity to market movements; it does not prevent sharp company-specific losses or establish that the stock is undervalued.
YOU MUST READ THIS: Top 6 Small-Cap Healthcare Stocks to Buy Right Now
Disclosure: No material interests to disclose. This article was originally published on BioTech HealthX.
